Related Experiment Video

Updated: Jun 16, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
14:56

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Published on: May 6, 2022

Matrix Metallopeptidase 2 Gene Polymorphism is Associated with Obesity in Korean Population

Dong Hee Han1, Su Kang Kim, Sungwook Kang

  • 1Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul 130-701, Korea.

The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology
|February 17, 2010
PubMed

Insights

Single nucleotide polymorphisms (SNPs) in the matrix metallopeptidase 2 (MMP2) gene show a significant association with overweight and obesity in the Korean population. These findings suggest MMP2 may play a role in obesity development.

Area of Science:

  • Genetics
  • Biochemistry
  • Obesity Research

Background:

  • Matrix metallopeptidase 2 (MMP2) is an enzyme involved in protein degradation, including basement membrane components.
  • Genetic variations, specifically single nucleotide polymorphisms (SNPs), can influence protein function and disease susceptibility.
  • Understanding the genetic basis of obesity is crucial for developing targeted prevention and treatment strategies.

Purpose of the Study:

  • To investigate the association between specific SNPs in the MMP2 gene and the risk of being overweight or obese.
  • To identify potential genetic markers within MMP2 that correlate with obesity in the Korean population.

Main Methods:

  • Genotyping of five selected MMP2 coding region SNPs (rs17242319, rs1053605, rs243849, rs2287074, and rs10775332) using the Golden Gate assay.
  • Analysis of genetic data from 142 overweight/obese individuals (BMI ≥23) and 145 normal-weight individuals (BMI 18 to <23).
  • Utilized statistical software (SNPStats, Haploview, HapAnalyzer, SNPAnalyzer, Helixtree) for genetic analysis, including linkage disequilibrium and haplotype analysis.

Main Results:

  • A linkage disequilibrium block was identified among four of the five genotyped SNPs (rs17242319, rs1053605, rs243849, and rs2287074).
  • Two synonymous SNPs, rs17242319 (Gly226Gly) and rs10775332 (Phe602Phe), demonstrated a significant association with overweight/obesity.
  • Haplotype analysis revealed a significant difference in a haplotype (CCCA) containing the rs17242319 polymorphism.

Conclusions:

  • The study suggests a potential association between MMP2 gene polymorphisms and overweight/obesity in the Korean population.
  • Specific SNPs within the MMP2 gene may serve as genetic markers for obesity risk.
  • Further research is warranted to elucidate the functional mechanisms linking MMP2 variations to obesity.
Keywords:
Body mass indexLinkage disequilibriumMatrix metallopeptidase 2ObesitySingle nucleotide polymorphism

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...